<code id='521103B97E'></code><style id='521103B97E'></style>
    • <acronym id='521103B97E'></acronym>
      <center id='521103B97E'><center id='521103B97E'><tfoot id='521103B97E'></tfoot></center><abbr id='521103B97E'><dir id='521103B97E'><tfoot id='521103B97E'></tfoot><noframes id='521103B97E'>

    • <optgroup id='521103B97E'><strike id='521103B97E'><sup id='521103B97E'></sup></strike><code id='521103B97E'></code></optgroup>
        1. <b id='521103B97E'><label id='521103B97E'><select id='521103B97E'><dt id='521103B97E'><span id='521103B97E'></span></dt></select></label></b><u id='521103B97E'></u>
          <i id='521103B97E'><strike id='521103B97E'><tt id='521103B97E'><pre id='521103B97E'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:comprehensive    Page View:6146
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In